Licensing

Welcome!

At Merck Frosst Canada Ltd., a subsidiary of Merck & Co. Inc., located in Whitehouse Station, NJ, we are strongly committed to partnership success. We recognize that the greatest achievements are not reached alone. They are the result of teamwork.

The philosophy of great achievements through teamwork is not new to us. We have a long tradition of successful partnerships. Alliances with innovative partners are an integral and essential part of our long-term business and research strategy. Our goal is for our partners and us to work together to accelerate the successful development and commercialization of breakthrough products that can bring meaningful improvements to patients' lives.

We understand that you have unique strengths to identify innovative therapeutic approaches. We are seeking partners with high quality science and subject matter and most important the enthusiasm to collaborate with us and share a vision to bring the best medicine to patients worldwide.

"We are serious about our commitment to strategic alliances. Our goal is for our partners and us to remain in the forefront of turning scientific breakthroughs into medicines that make a difference.   We have established a clear path to partnering, and invite you to explore the combination of your strengths with ours, and the successes we may share." Mervyn Turner, Ph.D. Senior Vice President Worldwide Licensing and External Research Merck & Co. Inc.

"Merck Frosst looks forward to partnering with Canadian research organizations that share the same level of commitment toward scientific excellence and the optimal care of patients" Dawn Graham, President, Merck Frosst.

"Neuromed is extremely pleased to partner with Merck and to have the opportunity to work with their scientific team. Their outstanding research, clinical development and marketing capabilities were significant factors in choosing Merck as a partner of choice." Christopher Gallen, M.D., Ph.D., President and Chief Executive Officer of Neuromed

This Web site contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. more >>